ReachRxResearch
Home
Research
Sign Up
  1. Home
  2. Research Hub
  3. Cross‐ancestry polygenic risk scores enh…

Cross‐ancestry polygenic risk scores enhance Alzheimer's disease risk prediction in multiethnic cohorts

Alzheimer's & Dementia·July 28Open Access
Clinical NeurologyPractice changingAlzheimer'S DiseaseCross-Sectional Genetic Association StudyGenomicsPolygenic Risk ScoreOlder Adult

Summary

View source

What was studied

This study compared single-ancestry (European), multi-ancestry (MAMA), and cross-ancestry Bayesian (PRS-CSx) polygenic risk scores for Alzheimer's disease (AD) across individuals of African, Amerindian, and European ancestry in two cohorts: ADSP (n=19,398; 7,111 AD cases, 12,287 controls) and HABS-HD (n=2,559). Models were evaluated for AD risk prediction, cognitive function, CSF/plasma biomarkers, and neuropathological burden within the A/T/N framework.

Key findings

The cross-ancestry Bayesian PRS-CSx model showed the strongest performance in non-European groups: OR 1.71 (95% CI 1.52–1.93) in African ancestry and OR 1.29 (95% CI 1.21–1.37) in Amerindian ancestry, with significantly higher R² than single-ancestry models (ΔR² p=4.6×10⁻⁷ vs. EUR PRS in African ancestry). Single-ancestry EUR PRS showed no significant association in African ancestry participants (OR 1.08, p=0.22). PRS-CSx also linked to lower CSF Aβ42, poorer cognition across all three domains, and the most severe CERAD/Thal/Braak neuropathology categories. An AD latent variable (pTau181 + Aβ PET) was significantly associated with PRS-CSx in the full HABS-HD cohort (SEM CFI=0.983, RMSEA=0.037).

Study limitations

- Non-European GWAS training datasets were substantially smaller than European datasets, limiting power for ancestry-specific models. - South and East Asian ancestry groups were too small for inclusion, restricting generalizability beyond African, Amerindian, and European groups. - Genotype–environment interactions were not modeled, and all cohorts were US-based, limiting global transportability.

Clinical implications

European-only AD polygenic risk scores should not be used for risk stratification in patients of African or Amerindian ancestry, as they fail to predict AD risk in these groups. Clinicians and researchers working with diverse populations should use cross-ancestry Bayesian PRS models (e.g., PRS-CSx) combined with ancestry normalization to improve equitable risk prediction.

Related Questions

Explore related topics

How do cross-ancestry polygenic risk scores compare to European-only PRS for Alzheimer's disease in Black and Hispanic patients?What is the best method to calculate and normalize polygenic risk scores in admixed or multiethnic populations?Can Alzheimer's disease polygenic risk scores predict amyloid and tau biomarker abnormalities before clinical diagnosis?

Publication Details

Year
2026
Journal
Alzheimer's & Dementia
Sample Size
n=21,957
Source
View article
Keep scrolling
More content below.
Up Next